Liver X Receptors in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential
4 affiliations
- 1Department of Pharmaceutical Engineering, School of Food and Pharmaceutical Engineering, Zhaoqing University, Zhaoqing 526061, China
- 2Department of Pharmacology of Chinese Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
- 3Key Laboratory for Research and Utilization of Southern Medicine, Zhaoqing University, Zhaoqing 526061, China
- 4Risk Assessment Laboratory for Agricultural Product Quality and Safety, Ministry of Agriculture and Rural Development, Zhaoqing University, Zhaoqing 526061, China
Abstract
Liver X receptors (LXRs), comprising LXRα and LXRβ, are oxysterol-responsive nuclear receptors that regulate cholesterol homeostasis and inflammatory signaling. In the central nervous system (CNS), LXR activity influences amyloid-β metabolism, glial responses, synaptic integrity, myelination, and blood–brain barrier function. This narrative review synthesizes shared and disease-specific mechanisms across neurodegenerative and demyelinating disorders, distinguishing established experimental effects from proposed pathways. We compare representative LXR modulators by receptor and transcriptional selectivity, CNS exposure, efficacy, and safety. Particular attention is given to hepatic lipogenesis caused by systemic LXRα activation and to LXRβ-selective or function-selective ligands, brain-targeted delivery, combination strategies, and biomarker-guided patient stratification. Although preclinical findings support therapeutic potential, clinical efficacy remains unproven. Priorities include cell-type-specific causal validation, quantitative CNS target engagement, and long-term safety assessment.
Related
- Epigenetic Mechanisms in Neurodegenerative Diseases: From Genetic Regulation to Therapeutic Potential
- Cuproptosis: New Mechanisms Linking Endothelial Dysfunction to Neurodegenerative Diseases and Therapeutic Prospects
- Telomeres, Aging and Neurodegenerative Diseases: Molecular Mechanisms, Clinical Evidence and Therapeutic Perspectives
- Mitochondrial Dysfunction in Neurodegenerative Diseases: Molecular Mechanisms, Primary Drivers Versus Early Amplifiers, and Emerging Mitochondria-Targeted Therapeutic Strategies
- Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases.
BibTeX
@article{li2026liver,
title = {{Liver X Receptors in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential}},
author = {Hancheng Li and Jinwei Gan and Peng Zeng and Chaohua Luo and Wenhua Liu and Hongwu Wang and Zhixian Mo},
journal = {Biomolecules},
year = {2026},
month = nov,
doi = {10.3390/biom16111654},
url = {https://www.mdpi.com/2218-273X/16/11/1654},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Liver X Receptors in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential
AU - Hancheng Li
AU - Jinwei Gan
AU - Peng Zeng
AU - Chaohua Luo
AU - Wenhua Liu
AU - Hongwu Wang
AU - Zhixian Mo
PY - 2026
DA - 2026/11/12
JO - Biomolecules
DO - 10.3390/biom16111654
UR - https://www.mdpi.com/2218-273X/16/11/1654
AB - Liver X receptors (LXRs), comprising LXRα and LXRβ, are oxysterol-responsive nuclear receptors that regulate cholesterol homeostasis and inflammatory signaling. In the central nervous system (CNS), LXR activity influences amyloid-β metabolism, glial responses, synaptic integrity, myelination, and blood–brain barrier function. This narrative review synthesizes shared and disease-specific mechanisms across neurodegenerative and demyelinating disorders, distinguishing established experimental effects from proposed pathways. We compare representative LXR modulators by receptor and transcriptional selectivity, CNS exposure, efficacy, and safety. Particular attention is given to hepatic lipogenesis caused by systemic LXRα activation and to LXRβ-selective or function-selective ligands, brain-targeted delivery, combination strategies, and biomarker-guided patient stratification. Although preclinical findings support therapeutic potential, clinical efficacy remains unproven. Priorities include cell-type-specific causal validation, quantitative CNS target engagement, and long-term safety assessment.
SN - 2218-273X
ER -